CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Identifying effect modifiers of CAR-T cell therapeutic efficacy: a systematic review and individual patient data meta-analysis protocol.
Identifying effect modifiers of CAR-T cell therapeutic efficacy: a systematic review and individual patient data meta-analysis protocol.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
CAR-T 细胞疗法(CAR-T)是治疗血液系统恶性肿瘤的一种有前景且令人振奋的新疗法,而复发/难治性患者的预后仍然很差。临床试验中令人鼓舞的结果往往因患者对治疗反应的异质性以及包括细胞因子释放综合征在内的安全性问题而受到影响。识别导致这种异质性的特定患者或治疗相关因素,可能为该复杂且昂贵疗法的长期可持续性提供关键。个体患者数据荟萃分析(IPMDA)可能为高度异质性提供潜在解释。因此,我们的目标是对CAR-T 细胞疗法在血液系统恶性肿瘤患者中的应用进行系统评价和IPDMA,以探索CAR-T 细胞疗法的潜在效应修饰因素。方法与分析:我们将检索MEDLINE、Embase和Cochrane临床对照试验中心注册库。研究将由两名独立评价者先在摘要层面进行重复筛选,然后在全文层面进行筛选。我们将纳入任何针对血液系统恶性肿瘤患者的CAR-T 细胞疗法前瞻性临床试验。我们的主要结局是完全缓解,而感兴趣的次要结局包括总缓解、无进展生存期、总生存期和安全性。将从每项纳入试验中收集IPD,如数据缺失,将联系通讯作者/研究申办方。将进行标准的聚合荟萃分析,随后使用一阶段方法进行IPD荟萃分析。将使用改良的卫生经济学研究所工具评估纳入研究的偏倚风险。伦理与传播:识别可能作为 CAR-T 细胞疗效修饰因子的特征至关重要,有助于塑造该领域未来的临床试验。本研究结果将提交至同行评审科学期刊发表,在相关会议上展示,并与相关利益相关方共享。
BACKGROUND: Chimeric antigen receptor T cell therapy (CAR-T) represents a promising and exciting new therapy for hematologic malignancies, where prognosis for relapsed/refractory patients remains poor. Encouraging results from clinical trials have often been tempered by heterogeneity in response to treatment among patients, as well as safety concerns including cytokine release syndrome. The identification of specific patient or treatment-specific factors underlying this heterogeneity may provide the key to the long-term sustainability of this complex and expensive therapy. An individual patient data meta-analysis (IPMDA) may provide potential explanations for the high degree of heterogeneity. Therefore, our objective is to perform a systematic review and IPDMA of CAR-T cell therapy in patients with hematologic malignancies to explore potential effect modifiers of CAR-T cell therapy. METHODS AND ANALYSIS: We will search MEDLINE, Embase, and the Cochrane Central Register of Controlled Clinical Trials. Studies will be screened in duplicate at the abstract level, then at the full-text level by two independent reviewers. We will include any prospective clinical trial of CAR-T cell therapy in patients with hematologic malignancies. Our primary outcome is complete response, while secondary outcomes of interest include overall response, progression-free survival, overall survival, and safety. IPD will be collected from each included trial and, in the case of missing data, corresponding authors/study sponsors will be contacted. Standard aggregate meta-analyses will be performed, followed by the IPD meta-analysis using a one-stage approach. A modified Institute of Health Economics tool will be used to evaluate the risk of bias of included studies. ETHICS AND DISSEMINATION: Identifying characteristics that may act as modifiers of CAR-T cell efficacy is of paramount importance and can help shape future clinical trials in the field. Results from this study will be submitted for publication in a peer-reviewed scientific journal, presented at relevant conferences and shared with relevant stakeholders.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。